Docetaxel is a chemotherapeutic drug which has recently demonstrated high efficacy in the treatment of a wide variety of tumors. Numerous novel targeted drugs are being introduced in preclinical and clinical practice, aiming to directly inhibit pathways responsible for the maintenance of transformed and immortalized phenotypes of cancer cells. Herein we reported the efficacy and safety results of the most significant clinical trials evaluating different combinations and schedules of docetaxel plus biological therapeutics.
Keywords: Docetaxel, targeted therapy, solid tumors, EGFR, PDGFR, VEGFR, RTKI, BCL-2, safety, efficacy
Rights & PermissionsPrintExport